Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/02/2022* -- Results Q3 2022 -- 0.50 --
11/02/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
08/09/2022 -- Results Q2 2022 0.53 0.50 5.04%
08/09/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/10/2022 -- Results Q1 2022 0.47 0.49 -5.02%
05/10/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/22/2022 -- Results Q4 2021 0.42 0.41 3.28%
02/22/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/02/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/09/2022
Beat/Miss Upgrade
Return Since -3.85%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
URL https://www.halozyme.com
Investor Relations URL https://ir.halozyme.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
79.59%
-42.99%
105.1%
-27.79%
21.19%
140.9%
-5.85%
3.61%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.66%
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-38.83%
-44.57%
-56.37%
48.58%
-52.96%
5.47%
10.67%
-77.09%
25.05%
-61.17%
-88.94%
-77.05%
-79.57%
12.53%
-8.16%
83.59%
-25.73%
-35.79%
-38.13%
-31.16%
-24.87%
108.1%
-27.93%
-13.82%
-5.67%
As of October 05, 2022.

Profile

Edit
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
URL https://www.halozyme.com
Investor Relations URL https://ir.halozyme.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
APDSX 155.03M USD 8.67%
JGRQX 74.51M USD 1.76%
DIGGX 63.38M USD 1.75%
BIGZ 37.95M USD 1.69%
DCCCX 78.63M USD 1.11%
XBI 75.02M USD 1.07%
TQAAX 49.83M USD 0.74%
LABU 7.914M USD 0.62%
IWO 41.26M USD 0.48%
FSSNX 44.62M USD 0.26%
IWM 120.55M USD 0.24%
VTWO 13.08M USD 0.22%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter HALO Tweets